Latest news about Medi Caps
Medi Caps
31.70
-3.52(-9.99%)
Company Performance:
View Company Insights1D-9.99%
1M0.00%
6M0.00%
1Y0.00%
5Y0.00%
More news about Medi Caps
08Apr 26
Medi-Caps Limited Declares Non-Applicability of SEBI Large Corporate Debt Securities Framework
Medi-Caps Limited filed a declaration with BSE on April 8, 2026, confirming it does not qualify as a Large Corporate under SEBI's debt securities framework. With zero outstanding borrowings as on March 31, 2026, the company is exempt from compliance requirements under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144, with the filing authorized by Company Secretary Abhishek Jain and CFO Hemant Sethi.
04Apr 26
Medi-Caps Limited Announces SEBI Special Window for Physical Securities Transfer and Dematerialisation
Medi-Caps Limited has informed shareholders about SEBI's special window facility for transfer and dematerialisation of physical securities sold or purchased before April 1, 2019. The window will operate from February 5, 2026 to February 4, 2027, covering new applications and previously rejected requests. Transferred securities will be credited in demat mode only and subject to a one-year lock-in period. Shareholders must submit required documents to the company's RTA, Ankit Consultancy Private Limited.
11Feb 26
Medi-Caps Limited Reports Q3FY26 Results with Contrasting Standalone and Consolidated Performance
Medi-Caps Limited announced mixed Q3FY26 financial results with standalone operations turning profitable at ₹28.50 lacs while consolidated performance showed losses of ₹76.58 lacs. The Board of Directors approved these results on February 11, 2026, highlighting strong recovery in real estate division through shop sales at Medi-caps Business Park, contrasted by ongoing challenges in the pharma division operated through subsidiary Medgel Private Limited.
13Nov 25
Medi-Caps Limited Reports Mixed Financial Performance for Q2 and H1 FY2026
Medi Caps Limited announced unaudited Q2 FY2026 results, showing a mixed performance. Consolidated revenue dropped to Rs. 268.76 crore from Rs. 829.62 crore in Q2 FY2025. However, profit before tax increased to Rs. 182.15 crore from Rs. 31.23 crore. The company's Real Estate Division generated Rs. 99.78 lakh from shop sales at Medi-caps Business Park. The pharmaceutical segment faced challenges, while real estate showed positive momentum. The company's wholly-owned subsidiary, Medgel Private Limited, reported a net loss after tax of Rs. (210.80) lakh for the quarter.
05Aug 25
Medi Caps Limited Reports Q1 Loss, Schedules AGM and Announces Board Changes
Medi Caps Limited faced substantial challenges in Q1 ending June 30. Standalone operations reported no revenue and a net loss of Rs 39.75 lakhs. Consolidated results showed a 56.61% decrease in revenue to Rs 268.76 lakhs and a widened net loss of Rs 349.19 lakhs. The Pharma Division generated Rs 268.76 lakhs in revenue but reported a segment loss of Rs 308.14 lakhs. The Real Estate Division had no revenue and a loss of Rs 39.75 lakhs. The Board scheduled the 42nd AGM for September 18, appointed Joshi Sahay and Company as Secretarial Auditor, and proposed re-appointment of Mr. Dharmendra Solanki as Independent Director.
05Aug 25
Medi-Caps Limited Re-appoints Dharmendra Solanki as Independent Director for Second Term
Medi Caps Limited has announced the re-appointment of Dharmendra Solanki as Non-Executive Independent Director for a second five-year term, from February 5, 2026, to February 4, 2031, subject to shareholder approval. Solanki, with 27 years of experience in Accounts, Finance, and Taxation, holds Commerce degrees from Vikram University. The company also approved financial results, scheduled the 42nd AGM for September 18, 2025, and appointed Joshi Sahay and Company as Secretarial Auditor for a five-year term.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
Lupin
Mankind Pharma
1,840.00
(-1.13%)
9,322.00
(-1.23%)
4,965.50
(+0.72%)
1,119.10
(+0.12%)
1,366.00
(-0.53%)
1,969.00
(+1.23%)
1,165.50
(+1.97%)
1,679.80
(+0.68%)
2,095.00
(+0.83%)
2,280.00
(+1.86%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
